Skip to main content

Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice

Abstract

Objectives

To identify the patient subgroups benefitting the most from the modern strategy including molecular-targeted therapy among patients with metastatic renal cell carcinoma (mRCC) in clinical practice.

Methods

Retrospective analysis of 144 patients with mRCC diagnosed between 1992 and 2011 at Kyoto University Hospital was conducted. Multivariate analysis using the Cox proportional hazards model was conducted to identify prognostic factors associated with overall survival (OS). Subgroup analysis was conducted to identify patients who benefitted the most from molecular-targeted therapy.

Results

Independent factors associated with worse OS are: tumors of histological type other than clear-cell, decreased hemoglobin (Hb), elevated lactate dehydrogenase (LDH), elevated C-reactive protein (CRP), and metastases at ≥ 3 sites. Median OS of patients treated with molecular-targeted therapy alone or with prior immunotherapy and those treated with immunotherapy alone was 57, 45 and 28 months, respectively. Molecular-targeted therapy had more effect on OS than immunotherapy alone among female patients, patients with Memorial Sloan-Kettering Cancer Center (MSKCC) intermediate risk features, and patients with metastatic progression less than 1 year after initial diagnosis of RCC, compared with their counterparts.

Conclusions

The modern strategy including molecular-targeted therapy may improve OS in patients with mRCC and MSKCC intermediate risk features in clinical practice, relative to those with other risk features. However, the prognosis for patients with tumors of histological type other than clear-cell, decreased Hb, elevated LDH, elevated CRP, or metastases at ≥ 3 sites remains poor even in the modern molecular-targeted era. Novel treatment strategies are necessary to improve prognosis in these patients.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. 1.

    Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111

    PubMed  Article  Google Scholar 

  2. 2.

    Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931–1939

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  6. 6.

    Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Naito S, Yamamoto N, Takayama T et al (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57:317–325

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Shinohara N, Nonomura K, Abe T et al (2012) A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. Cancer Sci 103:1695–1700

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Shinohara N, Abe T, Mochizuki T, et al. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol. 2011 [E-pub ahead of print]

  12. 12.

    Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788–1795

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  13. 13.

    Ravaud A (2011) Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16(Suppl 2):32–44

    PubMed Central  PubMed  Article  Google Scholar 

  14. 14.

    Cohen RB, Oudard S. Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities. Invest New Drugs. 2012; 30: 2066–79

    Google Scholar 

  15. 15.

    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB (2010) Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol 33:217–220

    PubMed  Google Scholar 

  16. 16.

    Yildiz I, Sen F, Basaran M et al (2011) Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey. Jpn J Clin Oncol 41:1380–1387

    PubMed  Article  Google Scholar 

  17. 17.

    van der Veldt AA, Boven E, Helgason HH et al (2008) Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99:259–265

    PubMed Central  PubMed  Article  Google Scholar 

  18. 18.

    Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27:5794–5799

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Heng DY, Chi KN, Murray N et al (2009) A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 115:776–783

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Warren M, Venner PM, North S et al (2009) A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 3:281–289

    PubMed Central  PubMed  Google Scholar 

  21. 21.

    Shek D, Tomlinson B, Brown M, Brunson A, Pan CX, Lara PN (2012) Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. Clin Genitourin Cancer 10:93–98

    PubMed  Article  Google Scholar 

  22. 22.

    Ljungberg B, Cowan NC, Hanbury DC et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398–406

    PubMed  Article  Google Scholar 

  23. 23.

    NCCN Clinical Practice Guidelines in Oncology Kidney Cancer Version 2.2012. [cited 2012 July 20]; Available from: http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf

  24. 24.

    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530–2540

    CAS  PubMed  Google Scholar 

  25. 25.

    Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584–3590

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  26. 26.

    Casamassima A, Picciariello M, Quaranta M et al (2005) C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 173:52–55

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Saito K, Tatokoro M, Fujii Y et al (2009) Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol 55:1145–1153

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Fujita T, Iwamura M, Ishii D, et al. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol. 2012; 19: 908–13

    Google Scholar 

  30. 30.

    Figlin R, Sternberg C, Wood CG. Novel agents and approaches for advanced renal cell carcinoma. J Urol. 2012; 188: 707–15

    Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Osamu Ogawa.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLSX 24 kb)

Supplementary material 2 (PDF 108 kb)

About this article

Cite this article

Kamba, T., Yamasaki, T., Teramukai, S. et al. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice. Int J Clin Oncol 19, 505–515 (2014). https://doi.org/10.1007/s10147-013-0581-2

Download citation

Keywords

  • Immunotherapy
  • Molecular-targeted therapy
  • Prognosis
  • Renal cell carcinoma